Browse Articles
Discover research articles across all indexed journals
Self-optimized contact in air-robust thermoelectric junction towards long-lasting heat harvesting
Health related quality of life and its influencing factors in Chinese patients with ocular tumors
Impact of BRCA status in patients with castrate-resistant prostate cancer undergoing abiraterone +/- stereotactic body radiotherapy: ARTO trial.
397 Background: ARTO (NCT03449719) was a multicenter randomized phase II trial exploring the benefit of concomitant Abiraterone acetate and stereotactic body radiotherapy (SBRT) administration in oligometastatic castrate resistant prostate cancer patients (omCRPC). Both biochemical response and biochemical progression free survival (bPFS) were improved by the addition of SBRT in the experimental arm if compared to abiraterone alone. Here is presented a secondary analysis focusing on prognostic impact of BRCA alterations in enrolled patients. Methods: Patients affected by omCRPC (< 3 non-visceral metastatic lesions) were randomized 1:1 to receive either Abiraterone alone (ARM A) or associated with concomitant SBRT on all sites of disease (ARM B). Subgroup analysis focusing on BRCA positive, negative or BRCA untested patients were conducted. Results: Overall population consisted of 157 patients, 89 patients were tested for BRCA 1 and BRCA 2 alterations, of whom 80 and 9 patients resulted negative and positive, respectively. Sixty eight patients were untested. In the BRCA negative population, bPFS events were registered in 43 patients (72.1 and 32.4% of population included in ARM A and B, respectively). Six bPFS events were registered in BRCA positive population (80 and 50% of patients included in ARM A and B, respectively). In the BRCA untested population, 26 bPFS events were detected (52.9 and 23.5% of patients included in ARM A and B, respectively). No significant difference in terms of bPFS was detected between BRCA positive and negative patients (HR 0.93, p=0.86). Conversely, BRCA untested patients had a significant lower risk of biochemical progression (HR 0.58, p=0.02). Benefit of SBRT in the experimental arm was confirmed both in the BRCA negative and BRCA untested populations in terms of bPFS, with HR of 0.37 (95% CI 0.19-0.73) and 0.50 (95% CI 0.14-0.76), respectively. In BRCA positive patients, results were inconclusive due to limited sample size (HR 0.5, 95% CI 0.09-2.89). Conclusions: In a well selected cohort of omCRPC included in a prospective trial, benefit of SBRT was confirmed in BRCA negative and untested patients. Larger cohorts of BRCA positive omCRPC patients undergoing SBRT are needed to confirm these results in this scenario. Clinical trial information: NCT03449719 . Biochemical progression free survival (BPFS) results in the two trial arms according to BRCA status. BRCA negative BRCA positive(vs negative) BRCA untested(vs negative) N Events N Events HR (95%CI), p N Events HR (95%CI), p BPFS 80 43 9 6 0,93(0,39-2,19)p=0,863 68 26 0,58(0,35-0,94)p=0,028 arm A 43 31 5 4 0,86(0,30-2,44)p=0,773 34 18 1,07(0,24-4,85)p=0,926 arm B 37 12 4 2 0,64(0,36-1,15)p=0,135 34 8 0,56(0,23-1,38)p=0,207
Real-world epidemiology and clinical outcomes of bladder cancer patients in Spain: BLARWE multicenter study.
702 Background: Bladder cancer (BC) is one of the most prevalent oncologic diseases in the world, and its incidence in Spain is among the highest in Europe. The optimal management of patients with muscle-invasive bladder cancer (MIBC) and non-MIBC (NMIBC) remains challenging. Currently, there are clinical trials ongoing that have the potential to change the management of early BC and its standard of care. The aim of this study is to provide a comprehensive description of the epidemiology of BC in Spain, and to generate robust evidence on the clinical characteristics, treatment patterns and clinical outcomes of these patients in routine clinical practice. Methods: This multicenter observational study collected adult patients diagnosed with primary or recurrent BC between Jan 1, 2018, and Dec 31, 2018. Patients with histopathological confirmation were included from 16 participating sites, and real-world data was retrospectively collected from medical records. Three cohorts were included: Cohort 1: all cases of BC; cohort 2: high risk NMIBC patients; cohort 3: MIBC patients. The data from cohort 1 presented here includes the incidence of newly diagnosed BC (primary objective) and recurrent or progressive cases (secondary objective) at all stages (NMIBC, MIBC and mBC). Results: 2071 patients were included, with the information available up to the data cutoff on Sep 13, 2024. The median age was 72 years and 84.9% of patients were male. 66,1% of patients were newly diagnosed, while 33.9% were recurrences/progressions. Most patients had NMIBC (80.8%), while the remaining patients had MIBC (16.5%) and mBC (2.7%), respectively. Patient characteristics at diagnosis according to type of BC are presented in the table. 2.8% of patients received their first treatment within a clinical trial after de novo or recurrent disease. Results from cohorts 2 and 3 are scheduled to be presented in the third quarter of 2025. Conclusions: This is the first study of this size to present real-world data on the incidence of all stages of BC (NMIBC, MIBC and mBC) including newly diagnosed/relapsed cases, in Spain. Most patients (4/5) had NMIBC and almost 2/3 were newly diagnosed. By 2025, the final results of the study are anticipated to provide robust evidence on the clinical characteristics, treatment patterns, and clinical outcomes of these patients in routine clinical practice. Patient characteristics at index date (2018). NMIBC MIBC mBC Median age, years (range) 72.0 (20.0-102.0) 73.0 (37.0-101.0) 72.0 (46.0-95.0) Age <=70, N (%) 763 (45.6) 144 (42.1) 23 (41.8) Age >70, N (%) 910 (54.4) 198 (57.9) 32 (58.2) Gender (Male), N (%) 1410 (84.3) 296(87.1) 49 (89.1) New cases, N (%) 1072 (64.0) 264 (77.2) 33 (60.0) Recurrences/progressions, N (%) 602 (36.0) 78 (22.8) 22 (40.0) Enrolled in a clinical trial to receive first treatment after the index date N (%) 30 (1.8) 19 (5.6) 8 (14.5)
The prognostic significance of circulating tumor DNA in prostate cancer: A systematic review and meta-analysis.
214 Background: Circulating tumor DNA (ctDNA) has attracted increasing interest as a biomarker in multiple cancers. This study aimed to perform a systematic review and meta-analysis to evaluate the prognostic value of ctDNA in prostate cancer (PCa). Methods: An electronic search of PubMed, Embase, and the Cochrane library was conducted to identify eligible studies. Hazard ratios (HRs) and corresponding 95% confidence intervals (95%CIs) for progression-free survival (PFS) and overall survival (OS) were extracted for pooled analysis. Data were pooled using a fixed-effects or random-effects models based on the study heterogeneity. Subgroup analyses were performed according to disease status, study design, treatment regimen, and sequencing method. R software (version 4.2.2) was used for statistical analysis. Results: A total of 13 studies comprising 1946 patients with PCa were included. The pooled analysis showed that higher baseline ctDNA levels were associated with shorter PFS (HR 2.88, 95%CI 1.98-4.19, P<0.001) and OS (HR 2.57, 95%CI 1.66-3.97, P<0.001) in overall PCa patients. Subgroup analysis further indicated that the prognostic value of ctDNA levels remained consistent across different study designs, systemic treatment regimens, and sequencing methods. Additionally, elevated ctDNA levels were significantly correlated with shorter PFS (HR 2.56, 95%CI 1.69-3.87, P<0.001) and OS (HR 2.76, 95%CI 1.76-4.33, P<0.001) in the metastatic castration-resistant prostate cancer (mCRPC) setting. Conclusions: Our systematic review and meta-analysis demonstrated that higher ctDNA levels were associated with poorer survival outcomes in patients with PCa, suggesting that ctDNA may serve as a valuable prognostic biomarker in PCa.
Five-year follow-up of prostate specific membrane antigen PET/CT-guided salvage radiotherapy following radical prostatectomy: A single center retrospective analysis.
336 Background: Salvage radiation therapy (sRT) is standard of care for biochemically recurrent prostate cancer following radical prostatectomy (RP). In this setting, prostate specific membrane antigen (PSMA) PET/CT has superior sensitivity and specificity for identifying recurrent disease, especially at low prostate specific antigen (PSA) levels, and can guide target volume delineation for sRT. We set out to identify how PSMA PET/CT guidance impacts long term clinical outcomes following sRT. Methods: We retrospectively screened five prospective PSMA PET/CT studies conducted at the University of California, Los Angeles between 2016 and 2021 for patients who had a prior RP, were restaged with a PSMA PET/CT at their first biochemical recurrence (PSA >0.2 ng/mL), subsequently received sRT, and had at least 24 months of follow up from the start of sRT. Progression-free survival (PFS), freedom from distant progression, and overall survival (OS) were calculated from the start of sRT using the Kaplan-Meier method. Cox regression was used to calculate adjusted hazard ratios (aHRs) for PFS, adjusting for androgen deprivation therapy (ADT), age, pre-sRT PSA level, and use of whole pelvis radiotherapy (WPRT). Results: 113 patients who received sRT between December 2016 and March 2021 met inclusion criteria. Median PSA at PSMA PET/CT was 0.4 ng/mL (IQR, 0.3-1). Median time from RP was 19.9 mo. (IQR, 5.6-51.8 mo). On PSMA PET/CT, 19 patients (17%) were staged TrN0M0, 35 (31%) N1/M1a, 13 (12%) M1b-c, and 46 (41%) T0N0M0 (no visible disease). 76 (67%) received ADT and 70 (62%) received WPRT. Median follow-up was 59.4 mo. (interquartile range [IQR], 47.4-69.5 mo.). 57 (50%) had documented progression. Median PFS was 49.2 mo. (95% confidence interval [CI], 24.1-74.3 mo.). Median freedom from distant progression was 76.4 mo. (95% CI, 62.9-89.9 mo.). Median OS was not reached. The five-year OS rate was 97.1% (95% CI, 94.1-100%). T0N0M0 patients had the most favorable PFS (aHR relative to M1b-c cohort, 0.25) followed by TrN0M0 and N1/M1a patients (aHR relative to M1b-c cohort, 0.39 for both). Pre-radiotherapy PSA was not associated with PFS (aHR, 1.0; p =0.98). WPRT was significantly associated with improved PFS in TrN0M0 patients (aHR, 0.12; p =0.035) but not in T0N0M0 patients (aHR, 0.87; p =0.8). Among T0 N1/M1 patients, prostate bed irradiation was significantly associated with improved PFS (aHR, 0.25; p =0.005). Among T0N0M0 and TrN0M0 patients, ADT was not associated with improved PFS ( p >0.05 for both). Among N1/M1 patients, ADT was significantly associated with improved PFS (aHR, 0.37; p =0.02). Conclusions: PSMA PET/CT-guided sRT was associated with favorable long-term clinical outcomes. Exploratory analyses suggest a benefit for WPRT following a positive PSMA PET/CT and for ADT for N1 or M1 disease. Further prospective data are needed to confirm these findings.
Mitofusin 2 displays fusion-independent roles in proteostasis surveillance
Abstract Mitochondria are essential organelles and their functional state dictates cellular proteostasis. However, little is known about the molecular gatekeepers involved, especially in absence of external stress. Here we identify a role of MFN2 in quality control independent of its function in organellar shape remodeling. MFN2 ablation alters the cellular proteome, marked for example by decreased levels of the import machinery and accumulation of the kinase PINK1. Moreover, MFN2 interacts with the proteasome and cytosolic chaperones, thereby preventing aggregation of newly translated proteins. Similarly to MFN2-KO cells, patient fibroblasts with MFN2-disease variants recapitulate excessive protein aggregation defects. Restoring MFN2 levels re-establishes proteostasis in MFN2-KO cells and rescues fusion defects of MFN1-KO cells. In contrast, MFN1 loss or mitochondrial shape alterations do not alter protein aggregation, consistent with a fusion-independent role of MFN2 in cellular homeostasis. In sum, our findings open new possibilities for therapeutic strategies by modulation of MFN2 levels.
RETRACTED ARTICLE: Saudi calcium bentonite: a novel modifier for enhanced foamed underbalanced drilling performance
Barriers to and facilitators of first-line treatment intensification (TI) in metastatic castration-sensitive prostate cancer (mCSPC) by practice setting and intensification frequency: A sub-analysis of IMPLEMENT.
48 Background: First-line TI (i.e., androgen-deprivation therapy + chemotherapy, androgen receptor pathway inhibitors, or both) is recommended for mCSPC but is underutilized. Phase 1 of IMPLEMENT identified barriers to and facilitators of TI. Phase 2 prioritized these factors and identified resources to increase TI. This sub-analysis describes the results in academic and nonacademic settings, and among high and low intensifiers (physicians who use first-line TI in >50% vs ≤50% of patients, respectively). Methods: Phase 1: Semi-structured virtual interviews with 18 oncologists and 18 urologists, using an implementation science approach based on the Theoretical Domains Framework to analyze themes by setting and intensification frequency. Phase 2: Discrete choice experiment with 302 physicians who reviewed descriptions of potential resources across 12 scenarios and selected the most helpful for increasing TI. We used a mixed-effects logistic regression model to calculate a coefficient of helpfulness for each resource to identify those with the strongest impact on TI decisions. Results: Phase 1:Low intensifiers and nonacademic physicians more frequently reported barriers to TI. Low intensifiers had gaps in clinical trial knowledge, tended to reserve TI for later, and had low-intensifier peers; nonacademic physicians had concerns about side effects, cost, and impact on quality of life. High intensifiers and academic physicians more frequently reported facilitators such as good clinical support and anticipated regret about missing the best chance at improving survival. Phase 2: Significant differences were noted between high and low intensifiers in the utility of decision support and clinical trial summaries (Table). Conclusions: Decision support tools and databases of post-treatment options may help address barriers to TI and improve guideline-concordant care. Resource, mean COH (±SD) Academicn = 81 Nonacademicn = 221 High intensifiersn = 184 Low intensifiersn = 118 Database of post-treatment options 1.89(0.38) 1.80(0.38) 1.94(0.39) 1.65(0.36) Decision support tool linking patient characteristics to first-line treatment options 1.60(0.53) 1.75(0.53) 1.45*(0.52) 2.12*(0.51) Summaries of key clinical trial data 1.39(0.40) 1.25(0.44) 1.55*(0.44) 0.88*(0.37) Cross-specialty treatment guidelines 0.57(0.26) 0.59(0.25) 0.48(0.22) 0.75(0.30) Information comparing clinical outcomes of first-line vs later TI 0.41(0.21) 0.37(0.18) 0.40(0.19) 0.36(0.19) Tools to reduce administrative burden 0.13(0.06) 0.23(0.11) 0.18(0.10) 0.25(0.11) COH, coefficient of helpfulness (scaled to have average value of 1, i.e., >1: above average utility; <1: below average utility). * P < 0.05 from bootstrap testing of subgroup averages.
LEEP: A randomised, window of opportunity, neoadjuvant trial examining the pharmacodynamic effects of ribociclib prior to radical prostatectomy for high-risk, localised prostate cancer.
392 Background: Prostate cancer (PCa) remains the second leading cause of cancer death in men. Neoadjuvant pharmacodynamic studies facilitate rational decisions about which therapies should progress to phase 2/3 trials. CDK4/6 inhibitors are effective in breast cancer, but have not demonstrated the same efficacy in metastatic PCa. LEEP assessed the pharmacodynamic effects of ribociclib, a highly selective oral CDK4/6 inhibitor, in hormone-naïve, high-risk, localised PCa. Methods: This open-label, window of opportunity trial randomised participants at 3 Australian sites in a 4:1 ratio to an experimental or control group. Participants in the experimental group were to be treated with ribociclib 400mg daily for 21 days prior to radical prostatectomy (RP). The primary endpoint was a 50% reduction in Ki-67 expression from the pre-treatment biopsy compared to the RP. Immune cell changes in peripheral blood and tissue were also examined. Results: Between November 2018 and October 2022,33 patients were randomised to either ribociclib or control. 17 participants in the ribociclib group and 7 in the control group were evaluable for response (9 not evaluable due to surgical delays (including COVID shutdowns) or insufficient cancer in the biopsy). When examining a random selection of cancer areas, 10/17 (58%) participants had a greater than 50% reduction in Ki-67, compared to only 2/7 (29%) in the control group. When examining hot spot areas of cancer (i.e. areas with the highest proportion of positive cells on low power estimation), only 5/17 (29%) participants had a greater than 50% reduction in Ki-67, compared to 0/7 (0%) in the control group. In peripheral blood, there were reductions in CD1c and CD141 dendritic cells and myeloid derived suppressor cells over 4 times points in the ribociclib (p>0.05, 0.05 and 0.05 respectively) vs. control groups (p=0.46, 0.14 and 0.14). In patients treated with ribociclib, there was no difference in circulating regulatory T cells (p=0.67). Within the PCa tissue, there was a reduction in regulatory T cells in the ribociclib group compared to controls (p=0.07), but no change in adjacent non-cancerous tissue (p=0.701). There was no difference in M1 or M2 macrophages between the ribociclib and control groups (M1: tumour p=0.307, adjacent non-cancer p=0.334; M2: tumour p=0.168, adjacent non-cancer p=0.130). Conclusions: Following neoadjuvant treatment with ribociclib, >50% reductions in Ki-67 were more frequent among those treated with ribociclib than controls. Reductions in Ki-67 were uncommon in more proliferative areas. Changes in the immune environment were consistent with breast cancer studies. We hypothesise that the more proliferative areas of cancer are less responsive to CDK4/6 inhibitors and this may in part explain the lower observed efficacy in mCRPC than metastatic breast cancer. Clinical trial information: ACTRN12618000354280 .
Association between post-orchiectomy systemic inflammatory indexes and tumor characteristics in clinical stage I germ cell tumours.
643 Background: Approximately 25-30% of clinical stage I (CSI) GCT patients will experience disease relapse after orchiectomy. Adding adjuvant treatment will decrease relapse rate, however, on the contrary leads to over-treatment. Prognostic biomarkers such as lymph-vascular invasion (LVI) and/or embryonal carcinoma (EC) in non-seminoma (NSGCT) and rete testis invasion (RTI) and/or primary tumor size (PTS) in seminoma (SGCT) add limited value in treatment decision making. The aim of this study is to assess systemic inflammatory (SI) indexes and lactate-dehydrogenase (LDH) with clinico-pathological findings along with their prognostic impact. Methods: This is retrospective study, which included 159 diagnosed CSI GCT patients, who underwent active surveillance (AS) from June 2004 to November 2023. Medical records and pathology reports were collected retrospectively. Blood drawn must have been done less than 3 months since orchiectomy had been done. For survival analysis we used dichotomized values of studied biomarkers to “low” and “high” based on median value. Results: Median follow-up was 61 months (ranging from 1-230 months), with 2-years relapse free survival (RFS) 81.3% and 69.0% in SGCT and NSGCT respectively. We confirm inferior RFS among LVI presence compared to LVI absence in NSGCT ([HR]= 2.59, 95%CI (0.74-9.07), p=0.04). Trend to inferior RFS in NSGCT patients with EC predominance (≥50%) was observed as well ([HR]= 2.59, 95%CI (0.98-6.85), p=0.06). Prognostic impact of RTI and PTS(>4cm) in SGCT was not observed, p=0.24 and p=0.51, respectively. SI indexes were assessed among population, where higher neutrophil to lymphocyte ratio (NLR) value was associated with LVI presence and with advanced tumor stage in NSGCT. In SGCT, higher systemic inflammatory index (SII) level was associated with LVI presence as well as with advanced pathological stage. PTS (>4cm) was associated with higher LDH level among cohort of all studied patients, without significance among SGCT nor among NSGCT. Higher LDH value in NSGCT was also associated with EC predominance (≥50%). Conclusions: Our study for the first-time revealed associations of post-orchiectomy systemic inflammatory indexes and/or LDH in CSI GCT. Those new associations deserve further evaluation on larger cohort of CSI GCT to elucidate, whether, its associations in certain histology subgroups will improve stratification of risky population.
Assessing racial disparities in testicular cancer survival: Evidence from a nationwide cohort.
621 Background: Testicular cancer is one of the most common and curable malignancies in young men, with a 5 year survival rate of 95%. Limited research has explored long-term survival outcomes among Black men, given rarity of disease among this demographic. Our study aims to assess potential racial differences in overall survival (OS) and cancer-specific mortality (CSM) among testicular cancer patients using a large, equal access nationwide Veterans Affairs (VA) database, focusing on self-identified Black and White race. Methods: This retrospective study analyzed Black and White testicular cancer patients from the VA database utilizing Veterans Informatics and Computing Infrastructure (VINCI). Self-identified race was obtained from the VA Cancer Registry, with OS and CSM as the primary outcomes. CSM was identified using the National Death Index (NDI). NDI data is available through 12/31/2020, after which date all patients with continued follow-up were censored. Cox proportional hazard models were applied to examine the associations of race on OS and CSM, adjusting for relevant clinical factors such as cancer staging, Charlson Comorbidity Index (CCI), and receipt of adjuvant chemotherapy or radiation. All time to event analyses were done from time of testicular cancer diagnosis to outcome of interest. Results: We compared 1799 White patients to 118 Black patients. A total of 431 (22.49%) patients died, of whom 405 were White and 26 were Black. There was no statistically significant difference in survival at 10 years between Black and White individuals (80.4% vs 81.6%, p = 0.68). The multivariable cox-regression analysis showed no statistically significant difference between Black and White men. Of the 431 deaths, 72 were identified as CSM (71 White, 1 Black). There was no significant difference in 10-year cumulative incidence of CSM in Black and White individuals (0% vs 4.1%, p=0.12). Similarly, no significant differences were found for CSM between Black and White men in the multivariable analysis. Conclusions: Our study found no significant racial disparities in OS or CSM between Black and White testicular cancer patients in the VA healthcare system. As the VA represents an equal access to care setting, these findings may not be generalizable to the broader U.S. population, where disparities in care are more notable. Conversely, access to care may overcome known sociodemographic disparities that drive worse clinical outcomes. The analysis is limited by the small number of patients experiencing the event of interest. Future research should be conducted to validate the association between self-identified race and survival outcomes in more diverse healthcare settings.
Mechanisms of urate transport and uricosuric drugs inhibition in human URAT1
Abstract High urate levels in circulation lead to the accumulation of urate crystals in joints and ultimately inflammation and gout. The reabsorption process of urate in the kidney by the urate transporter URAT1 plays a pivotal role in controlling serum urate levels. Pharmacological inhibition of URAT1 by uricosuric drugs is a valid strategy for gout management. Despite the clinical significance of URAT1, its structural mechanism and dynamics remain incompletely understood. Here, we report the structures of human URAT1 (hURAT1) in complex with substrate urate or inhibitors benzbromarone and verinurad at resolution ranges from 3.0 to 3.3 Å. We observe urate in the central substrate-binding site of hURAT1 in the outward-facing conformation and urate is wrapped in the center of hURAT1 by five phenylalanines and coordinated by two positively charged residues on each side. Uricosuric compounds benzbromarone and verinurad occupy the urate-binding site of hURAT1 in the inward-facing conformation. Structural comparison between different conformations of hURAT1 reveals the rocker-switch-like mechanism for urate transport. Benzbromarone and verinurad exert their inhibitory effect by blocking not only the binding of urate but also the structural isomerization of hURAT1.
Design, synthesis, molecular docking and anticancer activity evaluation of methyl salicylate based thiazoles as PTP1B inhibitors
EORTC GUCG 2418 - STARBURST: Strategies for treatment adaptation following re-evaluation of the bladder after using primary neoadjuvant systemic therapies—An EORTC platform trial.
TPS880 Background: The standard treatment for patient with muscle-invasive bladder cancer (MIBC) consists of neoadjuvant systemic therapy (NAT) followed by radical cystectomy (RC) or trimodal therapy (TMT). Currently, patients are not routinely reassessed after NAT and proceed directly to local treatment, leading to a missed opportunity for patients with complete or near complete response to benefit from bladder sparing strategies. On the other hand, for the non-responders, it is a missed opportunity to early systemic escalation. The platform will involve multiple steps. First, Starburst-1 (SB-1) will aim to create an effective multimodal signature that can predict effectively pathological complete response to NAT. Once the signature is validated, we will develop Starburst-2 (SB-2) as a platform in which we will test different risk-adapted strategies based on the response post NAT. Methods: In SB-1, we will enroll in a phase II, single arm, prospective cohort, patients with newly diagnosed MIBC (pT2-T4a N0-1 M0). All patients will be treated with standard of care (SOC) NAT followed by RC. All patients will be assessed before NAT by a cystoscopy, TURBT, urine cytology, bladder multiparametric MRI (mpMRI) using the NacVi-RADS score, blood and urine liquid biopsy. After completing the NAT, each patient will undergo a cystoscopy (+/- biopsy), SOC clinical and radiological workup (TAP CT +/- PET-FDG), a mpMRI and blood/urine collection. The primary endpoint of SB-1 is to prospectively evaluate the accuracy of the NacVI-RADS score to predict the pathological complete response defined as the absence of muscle invasive disease (ypT≥2 vs ypT0/a/1). Kappa score agreement between the MRI staging and RC pathological staging will also be addressed. Secondary endpoints include the assessment of new biomarkers including blood circulating tumor DNA (ctDNA) and urine tumor DNA (utDNA), urine multiplex biomarkers, pathomics, radiomics and molecular alterations that could predict pathological response. In SB-2, de-escalation therapies and escalation therapies according to patients’ response to NAT will be tested in a prospective multi-arm cohort platform. NCT number: will be obtained before ASCO GU. Clinical trial information: Ongoing in clinical trials.gov.
Patient profiles as drivers of physician choice for first-line (1L) treatment (tx) in locally advanced or metastatic urothelial cancer (la/mUC): Perspectives from a US study.
719 Background: As the number of tx options for patients with la/mUC increases, physicians aiming to optimize tx choice and sequencing must make complex decisions. Although recommended options provide clinical benefits, each has a distinct toxicity profile that limits its use in routine clinical care. This study assessed physician perspectives for 1L la/mUC tx selection based on hypothetical patient and disease characteristics. Methods: Data were drawn from the Adelphi Real World mUC Disease Specific Programme, a cross-sectional survey that captured data from medical oncologists and urologists responsible for treating people with la/mUC in the US, from Jan-July 2024. Physicians self-reported which 1L tx option they would be most likely to prescribe based on patient and disease characteristics provided. Tx options presented were: platinum-based chemotherapy followed by avelumab maintenance (PBC & Ave), enfortumab vedotin plus pembrolizumab (EV & P), cisplatin/gemcitabine plus nivolumab (cis/gem & nivo), and other. Descriptive statistics were used for all analyses. Results: Of the 49 physicians who participated, 23 (47%) primarily worked in academic practices, 19 (39%) in community-based practices, and 7 (14%) in other care settings. At data collection, physicians were making tx decisions for a median of 24 patients with la/mUC (IQR, 10-44). Physicians most frequently reported that they would choose PBC & Ave for patients with liver disease (53%) and EV & P for patients with only lymph node involvement (55%). A breakdown of physician-reported 1L tx choices by patient/disease profile is presented in the Table. Conclusions: Despite the limited sample size, this real-world study provides contemporary insights into la/mUC tx choice among practicing US physicians in an evolving therapeutic landscape. We found heterogeneity in clinician-reported choices for 1L tx based on patient profiles, and inconsistency vs guideline recommendations. Multidisciplinary discussion and consensus are needed to support physicians in identifying patient profiles that may derive the greatest benefit from different 1L tx options while minimizing potential risks. Criteria that guide clinicians and inform policy decisions should evolve and gain broader acceptance as novel therapeutics are incorporated into routine care. Physician-reported 1L tx choice (N=49) Characteristic, n (%) PBC & Ave EV & P Cis/Gem & Nivo Other Liver disease 26 (53) 16 (33) 7 (14) - Visceral disease 18 (37) 25 (51) 6 (12) - Liver metastases 17 (35) 22 (45) 10 (20) - Frail/elderly patients 9 (18) 24 (49) 8 (16) 8 (16) Pre-existing peripheral neuropathy 15 (31) 25 (51) 3 (6) 6 (12) Diabetes 24 (49) 19 (39) 5 (10) 1 (2) Only lymph node involvement 19 (39) 27 (55) 3 (6) - Low tumor burden 15 (31) 21 (43) 12 (24) 1 (2) High tumor burden 20 (41) 19 (39) 10 (20) -
Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP).
TPS432 Background: Patients with prostate cancer treated with radiotherapy (RT) or radical prostatectomy (RP) as primary therapy may develop BCR, defined by a prostate-specific antigen (PSA) increase with no evidence of metastases on conventional imaging. Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) may detect lesions in patients with BCR. Patients with BCR are at high risk of disease progression, and lesions identified by PSMA PET/CT need effective treatment to delay progression. Darolutamide, a structurally distinct and highly potent androgen receptor inhibitor, significantly improved metastasis-free survival (MFS) and overall survival (OS) in patients with nonmetastatic castration-resistant prostate cancer (CRPC). ARASTEP (NCT05794906) will evaluate whether darolutamide when added to ADT improves radiologic progression-free survival (rPFS) by PSMA PET/CT vs placebo plus ADT in patients with BCR following primary therapy and PSMA PET/CT-positive lesions. Methods: Eligible patients were treated by primary RT or RP +/- adjuvant RT (ART) or salvage RT (SRT), present with high-risk BCR (PSA doubling time [PSADT] <12 months and PSA ≥0.2 ng/mL after primary RP [± ART/SRT] or PSA ≥2 ng/mL above nadir after primary RT only), and must have ≥1 PSMA PET/CT-positive lesion of prostate cancer without visible lesions on conventional imaging, and serum testosterone ≥150 ng/dL. Approximately 750 patients from 221 global sites will be randomized 1:1 to oral darolutamide 600 mg twice daily or placebo, both with ADT, for 24 months or until disease progression, unacceptable toxicity, or withdrawal of consent. Patients with detectable PSA values (≥0.2 ng/mL) after 24 months will continue study treatment until PSMA PET/CT progression by blinded independent central review (BICR). Stratification factors are PSADT <6 vs ≥6–<12 months, intent to treat baseline PSMA PET/CT lesions with image-guided RT/surgery (Yes vs No) and distant ± locoregional vs locoregional-only lesions. The primary endpoint is rPFS by PSMA PET/CT assessed by BICR. Secondary endpoints include MFS on conventional imaging by BICR, time to CRPC, OS, quality of life, and safety. As of October 2024, 248 patients have been randomized. Clinical trial information: NCT05794906 .
Understanding diversity and disparities in a real-world locally advanced/metastatic urothelial carcinoma (la/mUC): Clinical characteristics, genomic landscape, and self-reported social determinants of health (SDOH).
669 Background: Fibroblast growth factor receptor (FGFR) inhibitor therapy improves overall survival in LA/mUC patients with FGFR 2/3 alterations and prior systemic therapy including immune checkpoint inhibitors (ICI). The current treatment landscape is rapidly evolving with inequities in molecular testing and access to novel therapies. In the real-world, the genomic landscape, treatment patterns, and outcomes in LA/mUC have yet to be established. In this multicenter prospective cohort study, we examined the RW treatment patterns, outcomes, genomic profile, diversity, and SDOH in pts with LA/mUC. Methods: In this LA/mUC cohort, we assessed baseline characteristics, self-reported SDOH, clinical management patterns, and treatment outcomes (PFS, OS). Comprehensive genomic profiling (CGP), including FGFR1-4, of DNA and RNA from archived FFPE tissue were analyzed. Results: 42 pts with LA/mUC were enrolled from Apr – Sept 2024 (79% bladder; 21% upper tract). 93% (39/42) had distant metastases (18% visceral). Median age at diagnosis was 69 yrs and 79% were male. 23 (62%) completed a questionnaire. 96% self-reported as White/Caucasian, 4% as Indigenous. 26% live in a rural setting >1 hour from a cancer centre. 47% report financial stress. 30% report a family history of Lynch Syndrome related malignancies. In 35 pts who underwent CGP, 11 pts (31%) had FGFR alterations, comprised of FGFR1-3 fusions, amplification, or mutations (Table 1). 88% (37/42) of pts received first-line (1L) therapy, primarily CTx (78%), and 1 pt received an FGFR-inhibitor. 62% (23/37) received 2L therapy (83% ICI, of which 68% was maintenance avelumab). 8 pts received 3L (63% (5/8) antibody drug conjugate [ADC]). 2 pts received 4L (n=1 ADC, n=1 CTx); 1 pt received 5L (ICI). Median progression free survival (mPFS) was 7.6 mo (95% CI: 5.1 – 22.5), 6.6 mo [95% CI: 2.5 – NR] and 6.9 mo [2.1 – NR], for 1L, 2L, 3L, respectively, but not reached for 4L and 5L. 88% are alive with a median follow-up of 10.3 months. Overall survival was not yet reached. Conclusions: This RW analysis of pts with LA/mUC provides valuable insights into the genomic landscape, clinical characteristics, and SDOH within this population. The presence of targetable genomic alterations underscores the necessity for an equitable precision medicine approach in diverse LA/mUC pt populations to optimize outcomes. This study demonstrates the feasibility of collection of a comprehensive array of data and samples to guide a management for patients with LA/mUC. NGS results. FGFR Alteration (n=11) Number (%) FGFR1 amp (borderline) 1 (9) FGFR1::TBC1D22A fusion 1 (9) FGFR2::USP11 fusion 1 (9) FGFR3 mutation 3 (27) FGFR3::FGFR1 fusion 2 (18) Insufficient sample 3 (27)
Sea level since the Last Glacial Maximum from the Atlantic coast of Africa
Updated results from a phase I/II study of CBP-1018, a bi-ligand–drug conjugate (Bi-XDC) as late line therapy for patients with metastatic castration resistant prostate cancer (mCRPC).
161 Background: Patients (Pts) with mCRPC have a poor prognosis with limited treatment options, particularly those who have progressed after novel hormonal agents (NHA) and chemotherapy. CBP-1018 has demonstrated a well-tolerated safety profile based on 112 pts and preliminary efficacy in mCRPC at RP2D of 0.14mg/kg as shown in 2024ASCO and 2024ESMO. Here we report the updated safety data of 120 pts and efficacy at ≥0.14mg/kg including pts treated with prior 2 nd generation androgen receptor pathway inhibitor (ARPI) and taxane from the Phase I/II study. Methods: In this study, pts with progressive mCRPC after standard of care regardless of the number of prior therapies were enrolled. Response evaluation was undertaken per PCWG3 and RECIST v1.1. Primary endpoints were ORR, rPFS and safety. Results: As of cutoff date of 31-Aug 2024, a total of 120 pts were enrolled. 8.3% (10/120) of pts experienced treatment related adverse event (TRAE) leading to dose reduction and 4.2% (5/120) had TRAE leading to discontinuation. The AEs were consistent with the known safety profile, with the most common ≥G3 TRAE primarily being hematologic, which were transient and easily manageable. Typical common AEs seen with ADC were rarely observed; only 1 pt experienced treatment related visual acuity reduction and 11.7% (14/120) of pts experienced peripheral neuropathy. All of these TRAEs were G1. 76 pts were enrolled at ≥0.14mg/kg dose level (0.14mg/kg N=69; 0.16mg/kg N=7). 68.4% (52/76) with ECOG 1. 17.1% (13/76) had liver metastases and 15.8% (12/76) had lung metastases. Additionally, 67.1% (51/76) had received at least one prior taxane and at least one 2 nd generation ARPI, while 53.9% (41/76) had received ≥ 2 prior 2nd generation ARPIs. 21.1% (16/76) had received prior PARP inhibitors. Among 25 pts with target lesion (≥0.14mg/kg), ORR was 20% and DCR was 88.0%. Target lesion reduction was observed in 60% of pts. In the subset of 15 pts with prior taxane and 2 nd generation ARPI treated pts with target lesion (0.14mg/kg), ORR was 20% and DCR was 80%. Among 69 pts (0.14mg/kg), median radiographic progression-free survival (rPFS) has not yet been reached; 7-month rPFS rate was approximately 70%, and 12-month rPFS rate was about 60%. Among the 48 pts with prior taxane and 2 nd generation ARPI treated (0.14mg/kg), 7-month rPFS rate was around 66%. Conclusions: CBP-1018 shows potential as a viable therapeutic option for heavily treated mCRPC pts based on the superior rPFS and anti-tumor activity, warranting further evaluation in later phase III trials. Clinical trial information: NCT04928612 .